Form 4: Y-mAbs Therapeutics SVP Sells 5,000 Shares
SEC Form 4 Filing
Joris Wilms, SVP & Chief Operating Officer of Y-mAbs Therapeutics, sold 5,000 shares of common stock on August 26, 2024, at a price of $14.69 per share.
Summary
- On August 26, 2024, Joris Wilms, the SVP & Chief Operating Officer of Y-mAbs Therapeutics, sold 5,000 shares of the company's common stock.
- The sale price was $14.69 per share.
- Following the transaction, Wilms directly owns 30,600 shares of Y-mAbs Therapeutics.
- The transaction was reported on a Form 4 filing with the SEC on August 27, 2024.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of an insider stock sale. The sale itself doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine disclosure of an insider stock sale. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but it's a relatively small transaction and unlikely to have a significant impact.
Key Dates
| Date | Description |
|---|---|
| 08/26/2024 | Date of stock sale transaction |
| 08/27/2024 | Date of SEC Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.